









Markets
/
Stocks
/
nasdaq-lxeo
/

Lexeo Therapeutics Inc

LXEO

5.250USD

-0.400-7.08%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

129.51MMarket Cap

LossP/E TTM



Lexeo Therapeutics Inc

5.250

-0.400-7.08%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lexeo Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Lexeo Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 97 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 19.64.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lexeo Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

97 / 391

Overall Ranking

212 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Lexeo Therapeutics Inc Highlights

StrengthsRisks

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -2.18, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 65.42M shares, increasing 13.30% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 290.00 shares of this stock.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

19.636

Target Price

+247.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Lexeo Therapeutics Inc is 5.73, ranking 325 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.73

Change



Financials

3.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lexeo Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Lexeo Therapeutics Inc is 6.59, ranking 249 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.18, which is -75.17% below the recent high of -0.54 and -217.31% above the recent low of -6.92.

Score

Industry at a Glance

Previous score

6.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 97/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Lexeo Therapeutics Inc is 9.09, ranking 16 out of 391 in the Biotechnology & Medical Research industry. The average price target is 18.50, with a high of 30.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

9.09

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

19.636

Target Price

+259.64%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Lexeo Therapeutics Inc

LXEO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Lexeo Therapeutics Inc is 5.99, ranking 286 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.23 and the support level at 4.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.12

Change

-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.145

Sell

RSI(14)

31.455

Neutral

STOCH(KDJ)(9,3,3)

19.426

Neutral

ATR(14)

0.464

Low Volatility

CCI(14)

-74.413

Neutral

Williams %R

90.123

Oversold

TRIX(12,20)

-0.842

Sell

StochRSI(14)

40.311

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.574

Sell

MA10

5.801

Sell

MA20

6.392

Sell

MA50

6.788

Sell

MA100

8.066

Sell

MA200

6.840

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Lexeo Therapeutics Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.63%, representing a quarter-over-quarter increase of 34.60%. The largest institutional shareholder is The Vanguard, holding a total of 3.89M shares, representing 5.34% of shares outstanding, with 61.13% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

6.11M

+65.71%

RA Capital Management, LP

5.00M

Paradigm BioCapital Advisors LP

3.67M

BlackRock Institutional Trust Company, N.A.

2.00M

+19.65%

Vestal Point Capital, LP

3.25M

+0.68%

Frazier Life Sciences Management, L.P.

4.42M

Affinity Asset Advisors LLC

3.87M

+7.83%

The Vanguard Group, Inc.

Star Investors

2.23M

+11.16%

Citadel Advisors LLC

3.72M

+3.08%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lexeo Therapeutics Inc is 4.33, ranking 90 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.